Sparsity in the cell line drug combination data matrix (Fig. 1g) resulted as several drug combinations were selectively profiled in clinically relevant cancer cell lines, e.g., ESR1 inhibitors were predominantly combined with other drugs in estrogen receptor-positive breast cancer cell lines since these agents are standard of care within this cancer subtype. The gene discussed is ESR1; the disease is breast carcinoma.